Chapter 9 Drug Therapy for Hematopoietic Disorders

$2.50

Pay And Download the Complete Chapter Questions And Answers

Chapter 9  Drug Therapy for Hematopoietic Disorders

 

 

Complete chapter Questions And Answers
 

Sample Questions

 

 

1. A patient has a low erythrocyte count. How may a colony-stimulating factor affect the patient’s erythrocyte count?

  1. A)  It stimulates growth of red blood cells.
  2. B)  It suppresses T-cell production.
  3. C)  It inhibits protein synthesis.
  4. D)  It stimulates antibody production.

Ans: A
Feedback:
Colony-stimulating factors stimulate the production of red blood cells, platelets, granulocytes, granulocyte–macrophages, and monocyte–macrophages. Colony-stimulating factors will not suppress the T-cell production, inhibit protein production, or stimulate antibody production.

2. A patient is exposed to a viral infection. What role will interferon most likely play during this exposure?

  1. A)  It will stimulate B-lymphocyte activity.
  2. B)  It will interfere with stem cell multiplication.
  3. C)  It will stimulate growth of lymphoid cells.
  4. D)  It will interfere with virus replication.

Ans: D Feedback:

Interferons interfere with the ability of viruses in infected cells to replicate and spread to uninfected cells. Interferons will not stimulate B-lymphocyte activity, stem cell multiplication, or growth of lymphoid cells.

3. A patient has developed a decubitus ulcer on the coccyx. What defense mechanism is most affected by this homeostatic change?

  1. A)  The mucous membrane is affected.
  2. B)  The respiratory tract is affected.
  3. C)  The skin is affected.
  4. D)  The gastrointestinal tract is affected.

Ans: C
Feedback:
The body’s primary external defense mechanism is intact skin. The development of a decubitus ulcer allows for entry of microbial growth. The mucous membranes, respiratory tract, and gastrointestinal tract are not affected primarily.

Page 1

4. A patient is being administered chemotherapeutic agents for the treatment of cancer. Which of the following blood cells will be stimulated by the colony-stimulating factors in response to the effects of the chemotherapy?

  1. A)  White blood cells
  2. B)  Red blood cells
  3. C)  Phagocytes
  4. D)  Myocardial cells

Ans: B
Feedback:
Chemotherapeutic agents have the potential to decrease red blood cells and will result in the colony-stimulating factors stimulating the production of red blood cells. The colony-stimulating factors do not affect the white blood cell production, phagocytes, or cardiac cells.

5. A patient with chronic renal failure is prescribed filgrastim (Neupogen). What is the major effect of filgrastim (Neupogen)?

  1. A)  Decreases neutropenia related to chemotherapy
  2. B)  Decreases white blood cells related to infection
  3. C)  Decreases growth of blood vessels due to ischemia
  4. D)  Decreases platelet count related to bleeding

Ans: A Feedback:

Filgrastim (Neupogen) is used to stimulate blood cell production by the bone marrow in places with bone marrow transplantation or chemotherapy-induced neutropenia. Filgrastim does not decrease white blood cells in response to infection. Filgrastim increases growth of blood vessels related to ischemic heart disease. Filgrastim does not decrease platelet count related to bleeding.

6. A patient has been diagnosed with chronic renal failure. Which of the following agents will assist in raising the patient’s hemoglobin levels?

  1. A)  Epoetin alfa (Epogen, Procrit)
  2. B)  Pentoxifylline (Pentoxil)
  3. C)  Estazolam (ProSom)
  4. D)  Dextromethorphan hydrobromide

Ans: A
Feedback:
Uses of epoetin include the prevention and treatment of anemia associated with chronic renal failure, hepatic impairment, or anticancer chemotherapy. Pentoxifylline is used for intermittent claudication to maintain the flexibility of red blood cells. Estazolam is a benzodiazepine agent used short term for insomnia. Dextromethorphan hydrobromide is used to relieve cough.

There are no reviews yet.

Add a review

Be the first to review “Chapter 9 Drug Therapy for Hematopoietic Disorders”

Your email address will not be published. Required fields are marked *

Category: Tag:
Updating…
  • No products in the cart.